Before the markets opened Monday, Biogen Idec announced the FDA has extended its regulatory review for Plegridy by three months.…
Browsing: biotechnology
Before the markets opened on Monday, Alexion announced the outcome of the reimbursement negotiations with the French government and consequently…
Dynavax ended the fourth quarter with $189.4 million in cash, which, according to our model, should sustain operations into 2016.…
Achillion Pharmaceuticals, Inc. reported net loss for the quarter of $13.4 million with a per-share loss of $0.14 versus our…
Dynavax ended the fourth quarter with $189.4 million in cash, which, according to our model, should sustain operations into 2016.…